The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1533
November 6, 2017
View Complete Issue         Table of Contents 2019 
Lesinurad/Allopurinol (Duzallo) for Gout-Associated Hyperuricemia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Lesinurad/Allopurinol (Duzallo) for Gout-Associated Hyperuricemia
November 6, 2017 (Issue: 1533)
The FDA has approved Duzallo (Ironwood), a fixed-dose combination of the uric acid transporter 1 (URAT1) inhibitor lesinurad (Zurampic) and the xanthine oxidase inhibitor allopurinol (Zyloprim, and generics), for once-daily treatment of...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Lesinurad/Allopurinol (Duzallo) for Gout-Associated Hyperuricemia
Article code: 1533c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.